---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-033755"
form_type: "8-K"
ticker: null
cik: "0001403708"
company_name: "Evoke Pharma Inc"
filed_at: "2023-07-21T23:59:59+00:00"
generated_at: "2026-06-13T04:53:14.101097+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants Evoke Pharma extension to Nov 20, 2023 to meet equity requirement

## Summary
- Nasdaq extended deadline to Nov 20, 2023 to regain minimum $2.5M stockholders' equity.
- Company had stockholders' equity of $2.1M as of Mar 31, 2023, below the $2.5M requirement.
- Evoke submitted compliance plan on July 7, 2023; extension requires public evidence of compliance.
- Failure to comply by 10-K filing for Dec 31, 2023 could result in delisting from Nasdaq Capital Market.
- Company may appeal any delisting determination to a Hearings Panel, but no assurance of success.

## SEC filing metadata
- accession: 0000950170-23-033755
- form_type: 8-K
- cik: 0001403708
- company_name: Evoke Pharma Inc
- filed_at: 2023-07-21T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1403708/000095017023033755/0000950170-23-033755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1403708/000095017023033755/evok-20230719.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-033755
- JSON: https://secwatch.observer/filing/0000950170-23-033755.json
- Plain text: https://secwatch.observer/filing/0000950170-23-033755.txt

## Key facts
- Listing & Compliance Notices
  Evoke Pharma Inc received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: July 19, 2023, Nasdaq notified the Company that it has granted the Company an extension until November 20, 2023 to regain compliance. Under the terms of the extension, the Company must provide to the Nasdaq staff a publicly available report that evidences such compliance and otherwise comply with conditions included in the extension notice. If the Company fails to evidence compliance upon filing the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 with the Securities and Exchange Commission and Nasdaq, the Company may be subject to delisting from the Nasdaq Capital Mar
  evidence_url: https://www.sec.gov/Archives/edgar/data/1403708/000095017023033755/0000950170-23-033755-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.